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Abstract
Down syndrome (DS), which arises from trisomy of chromosome 21, is
associated with deposition of large amounts of amyloid within the central
nervous system. Amyloid accumulates in two compartments: as plaques within
the brain parenchyma and in vessel walls of the cerebral microvasculature. The
parenchymal plaque amyloid is thought to result in an early onset
Alzheimer’s disease (AD) dementia, a phenomenon so common amongst
people with DS that it could be considered a defining feature of the condition.
The amyloid precursor protein ( ) gene lies on chromosome 21 and itsAPP
presence in three copies in DS is thought to largely drive the early onset AD. In
contrast, intracerebral haemorrhage (ICH), the main clinical consequence of
vascular amyloidosis, is a more poorly defined feature of DS. We review recent
epidemiological data on stroke (including haemorrhagic stroke) in order to
make comparisons with a rare form of familial AD due to duplication (i.e. having
three copies) of the  region on chromosome 21, here called ‘dup-APP’,APP
which is associated with more frequent and severe ICH. We conclude that
although people with DS are at increased risk of ICH, this is less common than
in dup-APP, suggesting the presence of mechanisms that act protectively. We
review these mechanisms and consider comparative research into DS and
dup-APP that may yield further pathophysiological insight.
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Introduction
Down syndrome (DS), which is due to an extra copy of chromo-
some 21, is strongly associated with early onset Alzheimer’s 
disease (AD)1. This is likely due to the presence of three copies of 
the gene coding for the amyloid precursor protein (APP) situated on 
chromosome 21, resulting in typical pathological features of AD, 
including senile plaques, composed of small, insoluble fragments 
of APP referred to as amyloid β (Aβ), formed after cleavage by 
specific secretase enzymes. The ensuing neurocognitive decline is a 
striking clinical feature of DS.
Cerebral amyloid angiopathy (CAA) results from the deposi-
tion of amyloid within the walls of leptomeningeal and cerebral 
blood vessels2 and is present in more than 80% of AD brains at 
post mortem3. As in AD, this amyloid derives from APP and is 
also composed of Aβ fragments. The process of vascular amyloid 
deposition is largely silent; however, when severe, it may set off a 
cascade of events resulting in intracerebral haemorrhage (ICH), the 
main clinical consequence of CAA. CAA-related haemorrhages 
tend to affect the elderly and occur multiply and in cortical and sub-
cortical (lobar) regions4. Like AD, CAA occurs frequently in DS5; 
however, unlike AD dementia, CAA-ICH is not a well-established 
clinical phenomenon in people with DS.
If CAA-ICH is over-represented in people with DS compared with 
the euploid population, it is important as an avenue for research and 
also to clinicians to provide more appropriate care to this group. In 
this review, we consider the rates of CAA and ICH in individuals 
with DS and compare these with sporadic AD as well as a specific 
form of familial AD due to duplication of the APP region on chro-
mosome 21. Finally, we consider potential mechanisms for appar-
ent differences between these groups.
Intracerebral haemorrhage in Down syndrome: 
epidemiology
Until recently, data on CAA-ICH in DS have been limited. There 
are seven case reports of people with DS suffering severe ICH6–11. 
Their paucity and noteworthiness suggest that ICH is not part of 
the experience of clinicians caring for people with DS. However, 
several mortality studies have reported increased incidence of cer-
ebrovascular events in people with DS12,13 but failed to distinguish 
between ischaemic and haemorrhagic stroke types.
More recently, Sobey et al. reported population-level data on 
cardiovascular events in 4081 people with DS and 16,324 age-
matched controls14. Both ischaemic (risk ratio [RR] = 3.76, 95% 
confidence interval [CI] 2.39, 5.92) and haemorrhagic (RR = 3.31, 
95% CI 1.95, 5.60) strokes are reported as more common amongst 
people with DS than non-DS controls. The incidence rates for ‘any 
stroke’ were 1.3% in males and 2.3% in women aged 19 to 50. 
For those over 51 years, the corresponding values were 11.3% in 
males and 8.2% in women. For haemorrhagic stroke, the values 
were 3.8% in males and 3.3% in women older than 51. However, 
when corrected for existing cardiovascular risk factors (including 
hypertension, diabetes, smoking, cardiac arrhythmia, sleep apnoea, 
congenital heart disease, pulmonary hypertension, and Moyamoya 
disease), the increased risk is largely attenuated for ischaemic but 
not for haemorrhagic stroke. The authors propose that this excess 
risk may be accounted for by factors not adjusted for in the regres-
sion analysis, such as misclassification of ischaemic-haemorrhagic 
transformation or anticoagulation, but it is also possible that some 
of this increased risk for haemorrhagic stroke may be explained by 
the deposition of vascular amyloid seen in DS, supporting the view 
that CAA-ICH is relatively common in DS.
Amyloid precursor protein duplication
The genetic abnormality in DS thought to underpin AD and 
CAA is the triplication of the APP gene, along with the rest of 
chromosome 21. It is proposed that this increased ‘dose’ of APP 
provides extra substrate for Aβ production, which then is deposited 
as senile plaques in AD or vascular amyloid in CAA.
APP is cleaved to Aβ fragments by γ-secretase enzymes whose cat-
alytic subunit is coded for by PSEN1 and PSEN2 genes. There are 
many well-documented familial forms of AD caused by missense 
mutations in PSEN1, PSEN2, and the APP gene15 that modulate 
APP processing and increase Aβ deposition. Similarly, hereditary 
forms of CAA, such as the Dutch type CAA, result from missense 
mutations in the same three genes16.
In addition, a novel genetic form of AD has been recognised 
in the last 10 years arising from small internal chromosome 21 
duplications17–25. These rare copy number variants all result in 
three copies of APP, collectively known as duplication of APP 
(dup-APP)26, and lead to an APP overdose. In this sense, dup-APP 
differs from other forms of familial AD that are the result of point 
mutations in APP, PSEN1, or PSEN2. Meaningful comparison can 
be made with DS, as an additional copy of APP is present in both 
diseases; DS differs from dup-APP only in the number of other 
genes on chromosome 21 that are also trisomic.
The phenotype of dup-APP is one of a highly penetrant AD demen-
tia (frequently associated with seizures17,18,22) with an onset age 
of between 39 and 64 years26. Significantly, carriers of dup-APP 
suffer a strikingly high rate of ICH. We estimate that this occurs 
in approximately a third of the published cases (Table 1 and 
Figure 1). These haemorrhages are typical of CAA-ICH: multiple 
and in a lobar distribution. They represent a serious clinical event 
and are a frequent cause of death in those affected.
Comparison of DS and dup-APP groups shows that the additional 
copy of the APP gene is sufficient to produce both early onset AD 
and CAA-ICH. However, although haemorrhagic stroke appears 
to occur in a significant proportion of elderly people with DS 
(3.3% to 3.8%)14, people with dup-APP are much more profoundly 
affected; the occurrence rate is approximately 30% (i.e. nearly 
10 times higher than in DS). This suggests that triplication of the 
rest of chromosome 21 may provide partial protection against the 
pro-haemorrhagic effects of APP duplication.
Pathophysiological insights
Aβ is primarily deposited in the adventitia and media of involved 
arterioles, and severity of CAA is classified according to spread 
through the vessel wall: mild CAA is defined as Aβ in the adven-
titia and some deposits between smooth muscle cells in the media, 
which are restricted to the tunica media without death of smooth 
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muscle cells. Moderate CAA involves replacement of smooth 
muscle cells by Aβ and thickening of the media without disruption 
of the blood-brain barrier (BBB). Severe CAA is defined as exten-
sive Aβ deposition with fragmentation or double-barrelling of the 
vessel wall, fibrinoid necrosis, and formation of aneurysms27.
The order in which vessels are affected typically follows a particu-
lar sequence; the leptomeningeal arteries are the first to show signs 
of pathology, followed by penetrating arterioles in the neocortical 
grey matter. Furthermore, vessels in the posterior regions of the 
brain (such as the occipital lobe) are especially affected, although 
the frontal cortex has also been named as a relatively early site, fol-
lowed by vessels of the olfactory cortex, hippocampus, and cerebel-
lum, while deep grey and white matter are usually spared3,28,29.
ICH due to CAA is typically lobar, and recurrent or multiple, and 
may occur in the absence of other risk factors for haemorrhage, 
such as hypertension. Once haemorrhage has occurred, the result 
is extensive neuronal death as well as a local immune response 
from microglia, astrocytes, and other immune cells. The salience 
of ICH in the phenotype of dup-APP is mirrored by the severity of 
underlying CAA reported in neuropathology studies. In all 13 cases 
of dup-APP in which neuropathology has been studied (age range 
of 48 to 58 years), the histological grade of CAA was moderate to 
severe and CAA was found in every brain reported17,18,20,23. By con-
trast, CAA is not a universal finding in people with DS (Figure 2, 
data taken from 5). Although most post mortem examinations on 
people with DS over the age of 50 show CAA from a moderate to 
severe degree5,30–32, a significant proportion (approximately one in 
five) (Figure 1) remains completely unaffected by CAA.
These observations suggest a complex relationship between 
increased APP gene dosage and CAA-ICH; individuals with DS 
show an increased prevalence of CAA-ICH compared with the 
euploid population but lower prevalence compared with dup-APP 
individuals. This suggests some degree of protection, but the mech-
anisms mediating this relationship are as yet unknown. We will 
consider the possibilities in the following sections.
Table 1. Summary of intracerebral haemorrhage and dup-APP status in the known kindreds.
Country (reference) Summation of ICH and dup-APP status ICH percentage 
(cases/number)
France (Rovelet-Lecrux et al.17, 2006) Five kindreds 
14 cases confirmed dup-APP 
Four cases of ICH in confirmed dup-APP cases 
ICH in family 229 likely represents a dup-APP 
case, but genotyping was not done 
Two unspecified strokes in non-genotyped 
individuals
28% (4/14)
France (Wallon et al.24, 2012) Seven kindreds 
19 affected individuals 
Cases of ICH in six out of seven kindreds 
(unspecified total number)
32% (6/19)
The Netherlands (Sleegers et al.18, 2006) One kindred 
Four cases confirmed dup-APP 
No confirmed cases of ICH
0% (0/4)
Finland (Remes et al.76, 2004; Rovelet-
Lecrux et al.20, 2007)
One kindred 
14 affected cases (nine confirmed dup-APP) 
Five cases of ICH
36% (5/14)
UK (McNaughton et al.22, 2012) Five probands (confirmed dup-APP) 
One ICH
20% (1/5)
Japan (Kasuga et al.21, 2009) Two probands 
One case of ICH (on computed tomography 
scan of head)
50% (1/2)
Sweden (Thonberg et al.25, 2011) One proband 
No ICH
0% (0/1)
Spain (Lladó et al.23, 2014) One proband 
Presented with ICH
100% (1/1)
Total: 30% 
(18/61)
The third column gives the most conservative estimate of the proportion of cases, known to harbour duplication (i.e. having 
three copies) of the amyloid precursor protein region on chromosome 21 (dup-APP), that are also affected by intracerebral 
haemorrhage (ICH).
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Figure 2. Histological severity of cerebral amyloid angiopathy (system of Vonsattel et al.27) seen in post mortem studies of people with 
Down syndrome in different age groups. Age ranges are indicated above charts. Data are reproduced from 5.
Aβ 40 versus Aβ 42
The 40-amino-acid peptide Aβ (Aβ 40) is more soluble than the 
longer Aβ 42 peptide. Aβ 40 tends to be the major form of Aβ in the 
artery walls in CAA, whereas Aβ 42 is more prominent in plaques. 
The ratio of Aβ 40/42 seems to determine to some extent whether 
Aβ is deposited in brain parenchyma or in the vessel walls. In muta-
tions where Aβ 42 is the prominent form of Aβ, such as the Indiana 
and London APP mutations, vascular amyloid seems to be a less 
prominent feature than parenchymal plaques33. In contrast, a high 
Aβ 40/42 ratio may promote CAA3, as seen in CAA Dutch type34.
Cellular studies using cortical neurones generated from induced 
pluripotent stem cells harbouring APP duplication or DS (trisomy 
of chromosome 21) have addressed the issue of Aβ 40/42 ratio. 
Both dup-APP35,36 and trisomy 2137,38 cells overproduce Aβ peptide 
compared with control cells, although the relative overproduction 
has not been compared in the same study protocol. Surprisingly, in 
dup-APP cells, the Aβ 40/Aβ 42 ratio is unchanged compared with 
control cells, which is also the case in mouse studies of overexpres-
sion of wild-type APP, resulting in an increase of both Aβ 40 and 
Aβ 42 with the ratio preserved34. In contrast, trisomic cells exhibit 
an increased Aβ 40/Aβ 42 ratio compared with dup-APP and 
control cells35.
In post mortem studies, the composition of vascular and paren-
chymal amyloid appears very similar in dup-APP and DS brains 
when stained with antibodies specific to either Aβ 40 or Aβ 42. 
Older individuals with DS30,31 and dup-APP cases17,19 have exten-
sive Aβ 40 deposition in vascular walls, preceded temporarily by 
low-level Aβ 42 deposition in DS31. Parenchymal plaques are 
present in both groups to a similar extent and stain mostly promi-
nently for Aβ 42.
Given the cellular data, it seems that the Aβ 40/42 ratio may be 
elevated in DS compared with dup-APP and controls; however, this 
is not reflected strongly in histopathology studies, which do not 
suggest significant differences in neuropathology between DS and 
dup-APP. An increased Aβ 40/42 ratio in DS would predict more 
severe CAA and predisposition to ICH; however, it does not explain 
the relative protection compared with dup-APP. Other mechanisms 
may be at play.
Aβ clearance in Down syndrome
Increased amyloid in the brain can be the result of either increased 
production or reduced clearance. As discussed in the preceding 
section, there is increased production of amyloid in both dup-APP 
and DS because of the presence of an extra copy of the APP gene 
in both cases. The Aβ 40/Aβ 42 ratios do not explain the appar-
ent difference between dup-APP and DS in severity of CAA and 
prevalence of ICH. It is possible that a difference in clearance of 
vascular amyloid is the key factor.
Aβ is cleared from the brain by several pathways: (1) endocytosis 
by astrocytes and microglial cells39, (2) enzymatic degradation40, or 
(3) removal through the BBB41 or along peri-arterial spaces42.
Microglia are the brain’s tissue macrophages; they have been shown 
to clear Aβ by endocytosis and internal degradation39. However, 
their exact role in this process is still poorly understood. Recent 
post mortem studies of brains from individuals with DS who were 
not older than 40 (i.e. before onset of AD) showed a heightened 
neuroinflammatory response, which was further increased in older 
individuals with DS and AD. Microglial cell activation increases 
with age in DS43 but may be lower compared with sporadic AD 
cases, despite higher levels of Aβ accumulation, and DS brains 
were characterised by a unique inflammatory phenotype associ-
ated with the formation of immune complexes (M2b)44. The authors 
hypothesised that accumulation of CAA may result in vascular 
leakage, with extravasation of IgG into the brain, which in turn 
may promote the M2b phenotype. Intriguingly, previous work by 
0-29 30-49 >50
Abscent SevereMild/moderate
Degree of histological severity of CAA in DS in different age groups
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this group showed that an M2b inflammatory phenotype induced 
by IgG infusions into brains of an amyloid mouse model promoted 
clearance of amyloid deposits, suggesting a protective mechanism45. 
However, if specific changes in neuroinflammation and microglial 
cells exist in DS, they have not yet been fully investigated and 
neither has the nature of these mechanisms been explored in 
dup-APP. Furthermore, since the bulk of extracellular Aβ clear-
ance is via the BBB or interstitial fluid flow46, it seems unlikely 
to be the main factor accounting for the relative protection against 
CAA-ICH in DS as compared with dup-APP.
Clearance of Aβ locally is also performed by the cerebrovascular 
smooth muscle cells and astrocytes through the low-density 
lipoprotein receptor-related protein-1 (LRP1)-mediated endocytic 
pathway47. The levels of LRP1 are reduced in patients with AD, 
and LRP1 levels also decline with age48. Recently, assays were 
developed to model these processes by using induced pluripotent 
stem cell models49. The effects of dup-APP and trisomy 21 on these 
processes are yet to be studied.
Physiological degradation of Aβ involves metallopeptidases such 
as neprilysin (NEP)46. NEP degradation of Aβ seems to be protec-
tive against CAA50. NEP expression in vascular smooth muscle 
cells is inversely correlated with degree of vascular Aβ51,52, and a 
polymorphism in the NEP promotor region that may reduce NEP 
transcription levels is associated with more severe CAA53. There 
is little published research on enzymatic degradation of Aβ in 
DS. However, one study by Miners et al. (2010) showed NEP 
levels to be increased in DS brains (age range of 10 to 80 years) 
compared with non-DS controls, and NEP level was strongly 
correlated with insoluble Aβ concentration54. This contrasts with 
evidence from sporadic AD showing decreased NEP immunoreac-
tivity compared with age-matched controls55. It is possible that in 
DS there is greater capacity for NEP expression conferring some 
protective effect against CAA.
Transport of Aβ across the BBB is receptor mediated. The low-
density lipoprotein pathway transports Aβ from the brain interstitial 
and cerebrospinal fluid compartments into the circulation56. To the 
best of our knowledge, specific abnormalities of the BBB have not 
been demonstrated in DS; however, lipid processing is known to 
be abnormal57, indirectly supporting the idea that BBB-mediated 
efflux of Aβ from the brain could be altered in this group.
A proportion of neuronally produced Aβ flows with the interstitial 
fluid along perivascular spaces to be excreted into the cerebrospi-
nal fluid and drained into the systemic circulation42. Although the 
contribution of perivascular drainage to CAA is by no means clear, 
it has been proposed to be a compensatory mechanism when other 
routes fail, and this may underlie the strong association between 
age and the development of CAA and AD pathology in the general 
population. Perivascular drainage is proposed to rely on counter-
current flow of lymphatics driven by the arterial pulsation58. As the 
arteries are increasingly affected by atherosclerosis or inflammation 
during ageing, they become more rigid with less effective contractile 
function and perivascular drainage. As individuals with DS appear 
to be somewhat protected against atherosclerosis57, this could be 
another protective mechanism, resulting in better Aβ drainage and 
less severe CAA.
Other potentially protective mechanisms
DS may be associated with several other protective mechanisms. 
It is possible that DS differs from dup-APP in the response to 
Aβ-related cell damage. Evidence from mouse model studies 
shows that immunotherapy against amyloid increases CAA and 
may also result in increased micro-haemorrhages59, suggesting an 
important role for the immune system in the pathophysiology of 
CAA. The innate immune system may differ in DS, thus affecting 
response to AB deposition. This possibility remains to be explored. 
Furthermore, the effect of free radicals may contribute to vascu-
lar damage, and although oxidative stress is a prominent feature of 
DS, it has been shown that increased activity of some anti-oxidant 
enzymes such as superoxide dismutase (SOD1, encoded on chro-
mosome 21 and triplicated in DS) is associated with less cogni-
tive decline, suggesting another potential protective mechanism60,61. 
In contrast, experiments using the Tg2576 mouse model have 
resulted in the suggestion that Aβ-induced oxidative stress causes 
DNA damage and excess opening of TRPM2 calcium channels, 
leading to calcium overload, which in turn results in endothelial 
dysfunction62.
Specific apolipoprotein E (APOE) genotypes (ε4 and ε2) are 
known risk factors for more severe CAA and ICH in the general 
population63–65. Two of the seven cases of ICH in DS report APOE 
genotype, both carrying high-risk variants (ε2/ε47 and ε4/ε49). This 
contrasts with dup-APP, where all 11 cases of ICH in which APOE 
genotype is reported carry a low-risk variant (ε3/ε3 n = 9, ε3/ε4 
n = 2). These very limited data suggest an importance of APOE 
genotype as a risk factor for CAA-ICH in DS and possible APOE 
independence of ICH in dup-APP; further investigation is needed. 
However, it is noteworthy that APOE is mapped to chromosome 
19, not chromosome 21, and this by itself is unlikely to explain 
differences between DS and dup-APP groups. In this regard, the 
ATP binding-cassette G1 (ABCG1) gene may be a more relevant 
candidate, as it is located on chromosome 21 and is thought to be 
responsible for cholesterol efflux onto apolipoproteins66. How-
ever, cellular studies provide conflicting evidence suggesting that 
ABCG1 overexpression may increase67 or reduce68 Aβ produc-
tion. Evidence from mouse models is also conflicting. One study 
examined transgenic mice with a sixfold overexpression of ABCG1 
that did not exhibit increased levels of Aβ69; by contrast, APOE ε4 
mice treated with bexarotene, an agent that indirectly upregulates 
ABCG1 and ABCA1, reversed hippocampal Aβ 42 deposition70. The 
evidence is unclear and its relation to CAA and ICH even more so.
Finally, individuals with DS of all ages are less at risk from 
hypertension than their peers in the general population (incidence 
rate ratio 0.3, 95% CI 0.3 to 0.4)71. Although hypertension has not 
(yet) been clearly related to CAA-ICH in DS and in fact gives rise 
to a different pattern of haemorrhage, it is theoretically possible that 
higher blood pressure may increase the likelihood of aneurism and 
bleeds in vessels severely affected by CAA in those with dup-APP 
compared with individuals with DS.
Further research
Further epidemiological data are needed in DS regarding haem-
orrhagic stroke—a diagnostic category, not a single entity. 
CAA-ICH can be distinguished from other forms of haemorrhagic 
stroke on clinical grounds by using the validated Boston criteria4. 
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The age-related risk for CAA-ICH in DS should be explored using 
susceptibility weighted imaging magnetic resonance imaging 
scans to detect microbleeds, which will allow comparison against 
dup-APP and sporadic AD to confirm relative burden of disease in 
these groups.
The role of factors involved in the clearance of Aβ in DS should 
be explored in more depth, as this could help to reveal potential 
drug targets to reduce CAA and associated ICH. Specifically, we 
have identified gaps in knowledge of the relationship between 
Aβ 40/Aβ 42 ratios and development of CAA and ICH in DS, on 
one hand, and Aβ clearance by endocytosis, enzymatic degrada-
tion, and removal through the BBB, on the other. Furthermore, 
direct comparison between DS and dup-APP cases and models 
is required. In this regard, mouse modelling with partial tripli-
cation of areas of chromosome 21 might identify an area of the 
chromosome that modulates the risk of CAA-ICH. CAA develops 
in several AD mouse models, including the Tg2576 (APP expressed 
under the PrP promoter)72, and J20 mouse model (APP transgenics 
with Swedish and Indiana mutations), particularly after 11 to 12 
months of age73,74. The Tg-SwDI mouse is the most widely used 
model for studying CAA, containing the Swedish, Dutch, and Iowa 
mutations and developing CAA at 6 months75. Therefore, different 
partial trisomy strains could be crossed to transgenic mice express-
ing forms of APP that give rise to CAA and micro-haemorrhages; 
double mutant progeny could be assessed for CAA to see whether 
regions of chromosome 21 mediate increased or reduced pathol-
ogy compared with mice carrying the APP transgene alone. If such 
a region were found, then it would give us dosage-sensitive can-
didate genes affecting the risk of CAA-ICH. Table 2 summarises 
some of the important unanswered questions generated by this 
review.
Conclusions
There is much variation between individuals with DS and devel-
opment of clinical dementia and associated CAA and ICH. Vari-
ability in phenotypic and pathological expression, however, is not 
unique to DS but has also been reported in familial AD, suggest-
ing the presence of genetic and non-genetic factors with disease- 
modifying effects. Intriguingly, individuals with DS appear to have 
much lower risk for developing ICH as well as some indications 
of less severe CAA when compared with families with dup-APP, 
despite also having three copies of the APP gene, suggesting that 
other genes on chromosome 21 may provide some protection 
Table 2. Summary of further research questions resulting from this review and corresponding suggestions for further 
enquiry.
Further research questions Possible investigative strategy
What is the true age-related prevalence 
of CAA-ICH in individuals with DS?
1.  Further epidemiological studies comparing DS against general AD population 
and dup-APP are required 
2.  Susceptibility weighted imaging magnetic resonance imaging studies to detect 
microbleeds in DS population
Is there a region of chromosome 21 that 
specifically modifies the risk of CAA?
Different partial trisomy mouse strains could be crossed with transgenic mice 
expressing forms of APP that give rise to CAA; double mutant progeny could be 
assessed for CAA and micro-haemorrhage
Does clearance of Aβ in DS differ from 
dup-APP? 
1.  Establish the relationship between Aβ 40/Aβ 42 ratios and development of CAA 
and ICH in DS by using neuropathological studies
2.  Experimental studies of Aβ clearance by endocytosis, enzymatic degradation, 
and removal through the blood-brain barrier by using animal and cellular models
3.  Compare DS and dup-APP by using neuropathological and cellular studies and 
animal models
What is the role of APOE genotype in 
CAA-ICH in the DS population and in 
dup-APP?
Population-based cohort study in DS individuals stratified by APOE genotype with 
imaging-confirmed micro-haemorrhage or ICH as the main outcome measure; 
collect similar data in families with dup-APP 
To what extent do other factors 
influence CAA development in DS?
1.  Explore the relationship between the immune system and CAA-ICH by using 
genomic, neuropathological, and immunological studies
2.  Explore the role of oxidative stress, and in particular antioxidant enzymes such 
as SOD, in CAA-ICH using mouse model experiments and longitudinal human 
biomarker studies
3.  Explore the role of vascular risk factors such as blood pressure in ICH in DS by 
using population-based epidemiological studies
Aβ, amyloid-beta; AD, Alzheimer’s disease; APOE, apolipoprotein E; APP, amyloid precursor protein; CAA, cerebral amyloid angiopathy; DS, 
Down syndrome; dup-APP, duplication (i.e. having three copies) of the amyloid precursor protein region on chromosome 21; ICH, intracerebral 
haemorrhage; SOD, superoxide dismutase.
Page 8 of 12
F1000Research 2016, 5(F1000 Faculty Rev):876 Last updated: 25 DEC 2016
against the effects of APP overdose. This review of the literature 
suggests that this lower prevalence and seemingly protective effect 
of trisomy 21 may be related to a difference in the clearance of Aβ, 
although other factors such as neuroinflammation, atherosclerosis, 
oxidative stress, and lower blood pressure could also have a role. 
Insights into these factors may provide important information about 
mechanisms of disease, which can be exploited to identify treat-
ment strategies. For example, if it turns out that low blood pressure 
helps to protect individuals with DS from ICH, then that would sug-
gest an important strategy to offer individuals from families with 
familial AD mutations at risk for CAA and ICH.
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